It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children’s Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.
Tag Archive: CTL019
CAR T-cell therapy tops this week’s research roundup, with news about the experimental immunotherapy designed to re-engineer a patient’s cells to fight cancer making late-breaking and captivating headlines across the nation.
Our latest research news roundup carries a hint of summer and exciting new beginnings.
The end of the year has come up fast, and so have important advances in pediatric research at Children’s Hospital of Philadelphia. This week’s In the News starts off with a celebration of two remarkable patients and their dedicated pediatric oncologist.
Your holiday season has been hectic, no doubt. Catch up with an early gift from us: Our biweekly roundup of research news from Children’s Hospital of Philadelphia comes with all the trimmings!
We like to highlight the whole range of research at The Children’s Hospital of Philadelphia, from basic discoveries at the lab bench to clinical findings applied at the patient’s bedside. But we have an abundance of updates to share today about the clinical side of research.
Researchers at The Children’s Hospital of Philadelphia reported their latest results from their studies of an investigational personalized cell therapy for a highly aggressive form of cancer, acute lymphoblastic leukemia (ALL).
Your immune system is designed to protect against foreign invaders such as infections, but you may not realize that it also destroys abnormal cells that your body produces.
The history of our understanding and approach to cancer are at the center of CANCER: THE EMPEROR OF ALL MALADIES, a film directed by Barak Goodman and executive produced by Ken Burns.
An innovative cell therapy for this stubborn form of leukemia continues to show highly promising results in children treated in a pilot clinical trial.